Your browser doesn't support javascript.
loading
Temporal evolution of metastatic disease: part II-a novel proposal for subcategorization of metastatic disease from non-neural solid tumors with diverse histologies and locations.
Yedururi, Sireesha; Marcal, Leonardo; Morani, Ajaykumar C; Katabathina, Venkata Subbiah; Jo, Nahyun; Rachamallu, Medhini; Prasad, Srinivasa.
Afiliação
  • Yedururi S; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Street, Unit 1473, Houston, TX, 77030, USA. syedururi@mdanderson.org.
  • Marcal L; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Street, Unit 1473, Houston, TX, 77030, USA.
  • Morani AC; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Street, Unit 1473, Houston, TX, 77030, USA.
  • Katabathina VS; Department of Radiology, The University of Texas Health Science Center at San Antonio, Floyd Curl Drive, 7703, San Antonio, TX, 78229, USA.
  • Jo N; Department of Internal Medicine, UAB Montgomery Regional Medical Campus, 2055 East South Blvd, Ste 200, Montogomery, AL, 36116, USA.
  • Rachamallu M; Department of Biomedical Engineering, The University of Virginia, 415 Lane Road, MR5 2010, Box 800759, Charlottesville, VA, 22908, USA.
  • Prasad S; Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Street, Unit 1473, Houston, TX, 77030, USA.
Jpn J Radiol ; 39(9): 844-856, 2021 Sep.
Article em En | MEDLINE | ID: mdl-33948787
ABSTRACT
Tumor spread is a continuous process and metastases can further disseminate. Currently, metastatic disease from most primary tumors is subcategorized as M0 if absent and M1 if present. However, metastatic disease in different locations may have different prognostic implications, even if it is from the same primary tumor. The current staging systems for metastatic disease have not evolved to match our understanding of the disease's evolution or the evolving treatment paradigms. Primary tumor-specific subcategorization of metastatic disease is currently available for a few tumors, but not all of them imply further remote spread of tumor, similar to tumor (T) and N (node) subcategorizations of the TNM staging, nor are they applicable to wide spectrum of other tumors. In this era of precision medicine, tumor-type agnostic therapies based on common biomarkers rather than primary tumor sites are emerging, but a subcategorization system applicable to metastatic disease from diverse primary tumor locations and with diverse histologies is not available. In this article, we discuss the need to further classify the metastatic disease and present a subcategorization applicable to metastatic disease from non-neural solid tumors from different primary tumor sites and with different histologies, which is based on the temporal spread of metastatic disease. Our proposed subcategorization scheme for metastatic disease into M0, M1, M2 and M3, is universally applicable to a diverse spectrum of non-neural solid tumors, and increasing M subcategorization represents further remote spread of tumor.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Jpn J Radiol Assunto da revista: DIAGNOSTICO POR IMAGEM / RADIOLOGIA / RADIOTERAPIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Jpn J Radiol Assunto da revista: DIAGNOSTICO POR IMAGEM / RADIOLOGIA / RADIOTERAPIA Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos